Skip to main content

Adding Cetuximab in Esophageal Cancer Fails to Improve Survival

Use of the epidermal growth factor receptor (EGFR) inhibitor cetuximab with chemoradiation did not improve overall survival (OS) in patients with esophageal carcinoma compared with chemoradiation alone, according to the results of the phase III RTOG 0436 trial.
http://www.cancernetwork.com/esophageal-cancer/adding-cetuximab-esophageal-cancer-fails-improve-survival

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino